CLRO Skyrockets 170% on Groundbreaking Reverse Merger Agreement with Cortigent

Shares of ClearOne Inc. (NASDAQ: CLRO) registered an extraordinary single-day performance yesterday, skyrocketing by more than 170% to dominate the domestic market’s leaderboard. The massive price action was catalyzed by an official corporate disclosure announcing a definitive reverse merger agreement with Cortigent, Inc., a specialized neurostimulation unit under the Vivani Medical umbrella.

Breaking Down the Structural Transaction

This merger formalizes ClearOne’s deliberate operational evolution into the deep medical technology sector. The technical roadmap details the following milestones:

• The New Vehicle: Cortigent will utilize ClearOne as a public corporate vehicle, operating moving forward under the new NASDAQ ticker symbol “CRGT”.
• Vivani’s Ownership Matrix: Upon closing, Vivani will receive roughly 12.5 million shares, asserting a controlling interest of up to 67.5% in the combined enterprise.
• Capital Sizing Pipeline: The management group is actively structuring a concurrent capital raise of up to $15 million to fund its breakthrough FDA-designated brain-implant device pipelines.

Order Book & Technical Evaluation

The explosive rally printed a major high-volume gap-up on the daily chart, breaking clear of long-term consolidation bands. Given that retail sentiment has transformed into an extremely bullish bias across social desks, short-term liquidity profiles have reached historic levels. Support has now structurally established near the breakout point, though near-term traders should expect localized volatility as the order book digests the initial liquidity imbalance.